Stock
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) TAK
Overview
TAK market data
Price History
TAK price chart · 1M
- O
- 18.22
- H
- 18.22
- L
- 17.98
- C
- 18.08
- Vol
- 43,948.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $18.22
- Previous Close
- $18.25
- Day High
- $18.22
- Day Low
- $17.98
- 52 Week High
- $18.48
- 52 Week Low
- $14.86
- 7 Day Return
- -0.25%
- 30 Day Return
- +2.99%
- 90 Day Return
- +13.18%
- 1 Year Return
- +10.86%
- Daily Notional Volume
- $794.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$96.75 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4,102.00 – $6,033.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.9T · P/B 1.21 · P/S 1.92.
Company News
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated SymptomsBenzinga · Aug 24, 2026, 1:28 PM
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · Aug 13, 2026, 5:07 PM
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’Benzinga · Aug 13, 2026, 8:33 AM
Department Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031Benzinga · Aug 10, 2026, 12:39 PM
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug ApprovalBenzinga · Aug 6, 2026, 3:16 PM
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA SchedulingBenzinga · Aug 5, 2026, 10:16 PM
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS TrialBenzinga · Jul 30, 2026, 8:03 PM
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B EstBenzinga · Jul 30, 2026, 12:11 PM
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585BBenzinga · Jul 30, 2026, 7:46 AM
Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B EstBenzinga · Jul 30, 2026, 7:44 AM